Insulin-Like Growth Factor 1 (IGF-1)
Also known as: Somatomedin C, IGF-I, Mechano-growth factor precursor
Overview
Insulin-Like Growth Factor 1 (IGF-1) is a 70-amino acid single-chain growth factor structurally homologous to insulin, primarily synthesized in the liver in response to growth hormone stimulation. IGF-1 mediates most of the anabolic effects of growth hormone including linear growth, muscle protein synthesis, and bone mineral accretion. Serum IGF-1 declines approximately 14% per decade after age 30, contributing to sarcopenia, reduced bone density, and metabolic changes associated with aging. Recombinant IGF-1 (mecasermin, Increlex) is FDA-approved for IGF-1 deficiency states.
Mechanism of Action
IGF-1 binds the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase structurally homologous to the insulin receptor. IGF-1R autophosphorylation activates IRS-1/2 adapter proteins, leading to PI3K → PDK1 → Akt → mTORC1 signaling (protein synthesis, cell survival) and Ras → MEK → ERK1/2 signaling (cell proliferation). In skeletal muscle, Akt-mTORC1 activation phosphorylates p70S6K1 and 4E-BP1, driving ribosome biogenesis and mRNA translation for muscle protein synthesis. IGF-1 also inhibits FoxO-mediated expression of MuRF-1 and MAFbx (atrogenes), preventing muscle protein breakdown.
Potential Benefits
- Skeletal muscle protein synthesis stimulation
- Bone mineral density maintenance
- GH-mediated anabolic effects (mediator)
- Neuroprotection and neurite outgrowth promotion
- FDA-approved for primary IGF-1 deficiency (mecasermin)
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | 40 mcg/kg SC 2x daily |
| Intermediate | 80 mcg/kg SC 2x daily |
| Advanced | 120 mcg/kg SC 2x daily (max) |
| Cycle Duration | Chronic during growth years |
FDA-approved (Increlex) for pediatric severe primary IGF-1 deficiency. Adult use off-label/research. Research peptides (IGF-1 LR3, DES IGF-1) are distinct modified forms.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Subcutaneous Injection ~100%
Inject just before or after a meal/snack to reduce hypoglycemia risk. Rotate sites.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Insulin-Like Growth Factor 1 (IGF-1):
Pediatric Growth Failure Protocol
Select cases of severe GH insensitivity (e.g., Laron syndrome) managed with IGF-1 replacement.
Research Muscle Stack (IGF-1 LR3)
Research combination layering IGF-1 LR3 with endogenous GH axis support (not FDA-approved, not Increlex).
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Refrigerate 2-8°C. Do not freeze. Discard 30 days after first use. |
|---|
No reconstitution needed (pharmaceutical Increlex).
Need exact syringe measurements?
Amino Acid Sequence
Gly-Pro-Glu-Thr-Leu-Cys-Gly-Ala-Glu-Leu-Val-Asp-Ala-Leu-Gln-Phe-Val-Cys-Gly-Asp-Arg-Gly-Phe-Tyr-Phe-Asn-Lys-Pro-Thr-Gly-Tyr-Gly-Ser-Ser-Ser-Arg-Arg-Ala-Pro-Gln-Thr-Gly-Ile-Val-Asp-Glu-Cys-Cys-Phe-Arg-Ser-Cys-Asp-Leu-Arg-Arg-Leu-Glu-Met-Tyr-Cys-Ala-Pro-Leu-Lys-Pro-Ala-Lys-Ser-Ala
Side Effects & Safety
- Hypoglycemia (most important; insulin-like activity)
- Jaw pain and facial bone growth at high doses
- Edema
- Potential cancer risk with prolonged supraphysiological levels (controversial)
- Acromegaly-like features with chronic excess
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Active Malignancy
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Pharmacokinetics
| Half-Life | ~5.8 hours (Increlex); ~12 min native free IGF-1 |
|---|---|
| Storage | Refrigerate at 2-8°C. Do not freeze. Protect from light. |
Synergistic Compounds
The following compounds have been studied alongside Insulin-Like Growth Factor 1 (IGF-1) for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA Staff Reviewers Say ‘No’ to 7 Compounded Peptides Ahead of July PCAC Vote
FDA staff reviewers urged against adding seven popular peptides to the 503A bulks list ahead of the July PCAC meeting, citing weak human data and safety uncertainty.
FDA reviewers urge ‘no’ on BPC-157, TB-500, MOTS-c ahead of July 2026 compounding vote
FDA reviewers’ June 29 briefings recommend against listing seven popular peptides for 503A compounding, citing limited human data and immunogenicity risk.
Medicare Starts Paying for Obesity Drugs Today — Bridge Program Opens $50 Access for Millions
Medicare's new $50 Bridge program covering Wegovy, Zepbound, Foundayo, and oral Wegovy for obesity launched July 1 — the first Medicare weight-loss benefit.
FDA staff urges caution on compounded peptides ahead of July advisory meeting
Ahead of the July 23–24 Pharmacy Compounding Advisory Committee meeting, FDA staff briefings recommend against listing seven popular peptides for compounding.